These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 9072602)

  • 21. Estramustine phosphate combined with orchidectomy as first-line therapy in patients with prostate carcinoma. Effect of age on survival.
    Pelger RC; Lycklama A Nijeholt Ga; Zwinderman AH; Hamdy NA
    Cancer; 2002 May; 94(10):2596-601. PubMed ID: 12173326
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral estramustine therapy in serum chromogranin A-positive stage D3 prostate cancer patients.
    Zaky Ahel M; Kovacic K; Kraljic I; Tarle M
    Anticancer Res; 2001; 21(2B):1475-9. PubMed ID: 11396235
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
    James ND; Caty A; Borre M; Zonnenberg BA; Beuzeboc P; Morris T; Phung D; Dawson NA
    Eur Urol; 2009 May; 55(5):1112-23. PubMed ID: 19042080
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The use of estramustine phosphate in the modern management of advanced prostate cancer.
    Ravery V; Fizazi K; Oudard S; Drouet L; Eymard JC; Culine S; Gravis G; Hennequin C; Zerbib M
    BJU Int; 2011 Dec; 108(11):1782-6. PubMed ID: 21756277
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of prognostic factors and efficacy in a phase-II study with docetaxel and estramustine for advanced hormone refractory prostate cancer.
    Nelius T; Reiher F; Lindenmeir T; Klatte T; Rau O; Burandt J; Filleur S; Allhoff EP
    Onkologie; 2005 Nov; 28(11):573-8. PubMed ID: 16249643
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Response to vinorelbine with or without estramustine as second-line chemotherapy in patients with hormone-refractory prostate cancer.
    Nakabayashi M; Ling J; Xie W; Regan MM; Oh WK
    Cancer J; 2007; 13(2):125-9. PubMed ID: 17476141
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The treatment of disseminated prostate cancer with estramustine.
    Rosenthal MA; Raghavan D; Stuart-Harris R; Ackland S; Grygiel J
    Aust N Z J Surg; 1992 Nov; 62(11):871-3. PubMed ID: 20169706
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma.
    Boccon-Gibod L; Fournier G; Bottet P; Marechal JM; Guiter J; Rischman P; Hubert J; Soret JY; Mangin P; Mallo C; Fraysse CE
    Eur Urol; 1997; 32(4):391-5; discussion 395-6. PubMed ID: 9412794
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.
    Fizazi K; Scher HI; Molina A; Logothetis CJ; Chi KN; Jones RJ; Staffurth JN; North S; Vogelzang NJ; Saad F; Mainwaring P; Harland S; Goodman OB; Sternberg CN; Li JH; Kheoh T; Haqq CM; de Bono JS;
    Lancet Oncol; 2012 Oct; 13(10):983-92. PubMed ID: 22995653
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Docetaxel, low-dose estramustine, and doxifluridine in hormone-refractory metastatic prostate cancer.
    Wada Y; Kikuchi K; Takahashi W; Honda J; Nakanishi J; Matsumoto K; Kuwahara T; Kai N; Kikukawa H; Ueda S
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):53-61. PubMed ID: 17375305
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of estramustine phosphate on free androgens. A comparative study of the effect of orchiectomy and estramustine phosphate on free androgens in patients with prostatic cancer.
    Van Poppel H; Werbrouck PW; Baert L
    Acta Urol Belg; 1990; 58(4):89-95. PubMed ID: 2093302
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer.
    Weitzman AL; Shelton G; Zuech N; Owen CE; Judge T; Benson M; Sawczuk I; Katz A; Olsson CA; Bagiella E; Pfaff C; Newhouse JH; Petrylak DP
    J Urol; 2000 Mar; 163(3):834-7. PubMed ID: 10687988
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
    Efstathiou E; Bozas G; Kostakopoulos A; Kastritis E; Deliveliotis C; Antoniou N; Skarlos D; Papadimitriou C; Dimopoulos MA; Bamias A
    Urology; 2005 Jan; 65(1):126-30. PubMed ID: 15667877
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Prostate-specific antigen as an evaluation method in the treatment of hormone-refractory cancer of the prostate].
    Morote J; Lorente JA; Vallejo C; Encabo G; López-Pacios MA; De Torres JA; Soler Rosello A
    Actas Urol Esp; 1994 Jun; 18(6):656-9. PubMed ID: 7524278
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of docetaxel plus estramustine in the treatment of patients with hormone-refractory prostate cancer.
    Matsumoto A; Inoue A; Yokoi S; Nozumi K; Miyazaki K; Hosoki S; Nagata M; Yamaguchi K
    Int J Urol; 2009 Aug; 16(8):687-91. PubMed ID: 19602005
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral estramustine phosphate and oral etoposide for the treatment of hormone-refractory prostate cancer.
    Numata K; Miura N; Azuma K; Karashima T; Kasahara K; Nakatsuzi H; Hashine K; Sumiyoshi Y
    Hinyokika Kiyo; 2007 Feb; 53(2):99-104. PubMed ID: 17352158
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effect of estramustine phosphate on hormone refractory prostate cancer].
    Tanaka M; Shiomi K; Hamano S; Suzuki N; Igarashi T; Murakami S; Shimazaki J
    Hinyokika Kiyo; 1997 Mar; 43(3):245-50. PubMed ID: 9127765
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical course of hormone refractory cancer of the prostate].
    Morote J; Vila J; López-Pacios MA; De Torres JA; Soler-Roselló A
    Actas Urol Esp; 1992 Oct; 16(9):722-5. PubMed ID: 1283286
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prior estrogen therapy as a predictor of response to subsequent estramustine-based chemotherapy in patients with androgen-independent prostate cancer.
    Garcia JA; Weinberg V; Small EJ
    Clin Prostate Cancer; 2005 Sep; 4(2):113-7. PubMed ID: 16197612
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer.
    Pili R; Häggman M; Stadler WM; Gingrich JR; Assikis VJ; Björk A; Nordle O; Forsberg G; Carducci MA; Armstrong AJ
    J Clin Oncol; 2011 Oct; 29(30):4022-8. PubMed ID: 21931019
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.